1. Confocal microscopy analysis of SK-BR-3 and HC cells treated with CF488A-labeled HER2-lytic hybrid peptide.
Confocal microscopy analysis of SK-BR-3 and HC cells treated with CF488A-labeled HER2-lytic hybrid peptide. A, confocal laser scanning microscopy of breast cancer cell line (SK-BR-3) and normal (HC) cells treated with CF488A-labeled HER2-lytic peptide (15 μmol/L) for 30 minutes; DIC, differential interference contrast microscope. B, quantification of HER2-lytic peptide binding to SK-BR-3 and HC cells treated with CF488A-labeled HER2-lytic peptide (15 μmol/L). Fold change in fluorescence intensity is the extent of binding of CF488A-labeled HER2-lytic peptide to each cell, relative to the fluorescence intensity values for untreated cells (control). C, SK-BR-3 and HC cells were treated with 15 μmol/L HER2-lytic hybrid peptide for 0, 5, 10, or 15 minutes, and cell viability was analyzed using WST-8 reagent.
Megumi Kawamoto et al. Mol Cancer Ther 2013;12:
©2013 by American Association for Cancer Research